BiotechTube

LP-10 (Liposomal Tacrolimus)

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Oral Lichen Planus

Conditions

Oral Lichen Planus

Trial Timeline

Jul 1, 2024 → Jun 1, 2025

NCT ID
NCT06233591

About LP-10 (Liposomal Tacrolimus)

LP-10 (Liposomal Tacrolimus) is a phase 2 stage product being developed by Lipella Pharmaceuticals for Oral Lichen Planus. The current trial status is active. This product is registered under clinical trial identifier NCT06233591. Target conditions include Oral Lichen Planus.

What happened to similar drugs?

5 of 20 similar drugs in Oral Lichen Planus were approved

Approved (5) Terminated (2) Active (14)
❌AL001 + Placebo + Open label - AL001AlectorPhase 3
🔄Micafungin + FluconazoleAstellas PharmaPhase 3
🔄micafungin + caspofunginAstellas PharmaPhase 3
🔄Erlotinib + PlaceboAstellas PharmaPhase 3
✅AmifostineSun PharmaceuticalApproved
🔄Teriparatide 20 mcgEli LillyPhase 3
✅tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved

Hype Score Breakdown

Clinical
12
Activity
12
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06233591Phase 2Active

Competing Products

20 competing products in Oral Lichen Planus

See all competitors
ProductCompanyStageHype Score
AL001 + Placebo + Open label - AL001AlectorPhase 3
22
AL001AlectorPhase 2
25
AG013OragenicsPhase 2
17
Micafungin + FluconazoleAstellas PharmaPhase 3
40
micafungin + caspofunginAstellas PharmaPhase 3
40
Erlotinib + PlaceboAstellas PharmaPhase 3
40
AmifostineSun PharmaceuticalApproved
35
exenatide + Other antidiabetic therapiesEli LillyPre-clinical
26
Teriparatide 20 mcgEli LillyPhase 3
40
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional PrednisoneEli LillyPhase 1/2
36
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
39
tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved
43
Essential oils + 0.2% chlorhexidine + Sterile waterJohnson & JohnsonApproved
43
galantamine hydrobromideJohnson & JohnsonPhase 2
35
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
40
Camrelizumab + Camrelizumanb plus TPFJiangsu Hengrui MedicinePhase 2
35
Camrelizumab plus TP + TPJiangsu Hengrui MedicinePhase 3
47
AZD1981 + Neovletta 21/28 + Placebo AZD1981AstraZenecaPhase 1
29
DurvalumabAstraZenecaPhase 1/2
36
fostamatinib + Microgynon® 30 (Oral contraceptive) + PlaceboAstraZenecaPhase 1
29